Publications

Search by keyword

Type

Member

featured publications

Pharmacokinetics and coagulation biomarkers in children and adults with hemophilia A receiving emicizumab prophylaxis every 1, 2, or 4 weeks.

29/12/2023 Research and practice in thrombosis and haemostasis

Authors: Anna Kiialainen, Joanne I Adamkewicz, Claire Petry, Johannes Oldenburg, Steven W Pipe, Guy Young, Johnny Mahlangu, Michaela Lehle, Markus Niggli, Giancarlo Castaman, Víctor Jiménez-Yuste, Midori Shima, Claude Négrier, Christophe Schmitt
View this publication
Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b, open-label trial.

21/12/2023 Blood

Authors: Steven W Pipe, Peter W Collins, Christophe Dhalluin, Gili Kenet, Christophe Schmitt, Muriel Buri, Victor Jiménez-Yuste, Flora Peyvandi, Guy Young, Johannes Oldenburg, Maria Elisa Mancuso, Kaan Kavakli, Anna Kiialainen, Sonia Deb, Markus Niggli, Tiffany Chang, Michaela Lehle, Karin Fijnvandraat
View this publication
Emicizumab for the Treatment of Acquired Hemophilia A: Consensus Recommendations from the GTH-AHA Working Group.

04/12/2023 Hamostaseologie

Authors: Christian Pfrepper, Robert Klamroth, Johannes Oldenburg, Katharina Holstein, Hermann Eichler, Christina Hart, Patrick Moehnle, Kristina Schilling, Karolin Trautmann-Grill, Mohammed Alrifai, Cihan Ay, Wolfgang Miesbach, Paul Knoebl, Andreas Tiede
View this publication
Interim analyses of the multinational real-world prospective cohort HEM-POWR study evaluating the effectiveness and safety of damoctocog alfa pegol in patients with hemophilia A.

24/10/2023 European journal of haematology

Authors: Mark T Reding, María Teresa Álvarez-Román, Giancarlo Castaman, Maissaa Janbain, Tadashi Matsushita, Karina Meijer, Kathrin Schmidt, Johannes Oldenburg
View this publication
Emicizumab prophylaxis in patients with acquired haemophilia A (GTH-AHA-EMI): an open-label, single-arm, multicentre, phase 2 study.

16/10/2023 The Lancet. Haematology

Authors: Andreas Tiede, Christina Hart, Paul Knöbl, Richard Greil, Johannes Oldenburg, Ulrich J Sachs, Wolfgang Miesbach, Christian Pfrepper, Karolin Trautmann-Grill, Katharina Holstein, Jan Pilch, Patrick Möhnle, Christoph Schindler, Carmen Weigt, Dorothea Schipp, Marcus May, Christiane Dobbelstein, Fabius J Pelzer, Sonja Werwitzke, Robert Klamroth
View this publication
Two-center validation of assays for the detection of binding and neutralizing anti-factor VIII antibodies.

12/10/2023 Haemophilia : the official journal of the World Federation of Hemophilia

Authors: Jens Müller, Sonja Neimanis, Jörg Kahle, Thilo Albert, Stephan Schultze Strasser, Bonita Rup, Bernd Pötzsch, Christoph Königs, Johannes Oldenburg
View this publication
Heterozygosity in FXIII genes and the manifestation of mild inherited FXIII Deficiency.

11/10/2023 Journal of thrombosis and haemostasis : JTH

Authors: Sneha Singh, Behnaz Pezeshkpoor, Muhammad Ahmer Jamil, Johannes Dodt, Amit Sharma, Vasanth Ramar, Vytautas Ivaskevicius, Emma Hethershaw, Helen Philippou, Anna Pavlova, Johannes Oldenburg, Arijit Biswas
View this publication
Functional determination of emicizumab in presence of Factor VIII activity.

21/09/2023 Journal of thrombosis and haemostasis : JTH

Authors: Nasim Shahidi Hamedani, Anouk Anna Marie Therese Donners, Matthijs van Luin, Simone Gasper, Heiko Rühl, Claudia Klein, Thilo Albert, Mohsin El Amrani, Bernd Pötzsch, Johannes Oldenburg, Jens Müller
View this publication
Cases of less-than-expected FVIII activity in previously treated patients during post-marketing surveillance of N8-GP.

20/09/2023 Haemophilia : the official journal of the World Federation of Hemophilia

Authors: Johannes Oldenburg, Gary Benson, Pratima Chowdary, Susan Halimeh, Tadashi Matsushita, Anne Nørland, Mohd Nawi Wahid, Laszlo Nemes
View this publication
Prophylaxis with a recombinant factor VIII Fc in hemophilia A: long-term follow-up on joint health, efficacy, and safety from phase 3 studies in children and adults.

22/08/2023 Research and practice in thrombosis and haemostasis

Authors: Barbara A Konkle, Johannes Oldenburg, John Pasi, Roshni Kulkarni, Beatrice Nolan, Johnny Mahlangu, Guy Young, Simon A Brown, Ingrid Pabinger, Amy Shapiro, Claude Négrier, Victor Blanchette, Margaret V Ragni, Jennifer Dumont, Stefan Lethagen
View this publication

First page
1
2
3
4
5
6
7
8
9
10
Last page

Pharmacokinetics and coagulation biomarkers in children and adults with hemophilia A receiving emicizumab prophylaxis every 1, 2, or 4 weeks.

Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b, open-label trial.

Emicizumab for the Treatment of Acquired Hemophilia A: Consensus Recommendations from the GTH-AHA Working Group.

Interim analyses of the multinational real-world prospective cohort HEM-POWR study evaluating the effectiveness and safety of damoctocog alfa pegol in patients with hemophilia A.

Emicizumab prophylaxis in patients with acquired haemophilia A (GTH-AHA-EMI): an open-label, single-arm, multicentre, phase 2 study.

Two-center validation of assays for the detection of binding and neutralizing anti-factor VIII antibodies.

Heterozygosity in FXIII genes and the manifestation of mild inherited FXIII Deficiency.

Functional determination of emicizumab in presence of Factor VIII activity.

Cases of less-than-expected FVIII activity in previously treated patients during post-marketing surveillance of N8-GP.

Prophylaxis with a recombinant factor VIII Fc in hemophilia A: long-term follow-up on joint health, efficacy, and safety from phase 3 studies in children and adults.